Breaking Finance News

GlaxoSmithKline PLC (LON:GSK) target price lowered to 1,900.00GBX, reported today by Jefferies International

Only yesterday GlaxoSmithKline PLC (LON:GSK) traded 0.49% lower at 1,590.00GBX. GSK’s 50-day moving average is 1,658.43GBX and its 200-day average is 1,524.87GBX. With the last close up 5.98% relative to the two hundred day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 13,339,146 shares of GSK traded hands, up from ann avg. trading volume of 8,806,050.

Jefferies International dropped the target price of GlaxoSmithKline PLC (LON:GSK) to 1,900GBX, stating a possible upside of 0.19%,

On 9/12/2016, HSBC released a statement about GlaxoSmithKline PLC(LON:GSK) maintained the target price at 1,970.00GBX. At the time, this suggested an upside of 0.24%.

See Graphic Below:

GlaxoSmithKline PLC (LON:GSK)

A total of 24 equity analysts have issued a report on the stock. Three analysts rate the stock a strong buy, six firms rate the stock a buy, 17 firms rate the stock a hold, two analysts rate the company to underperform, and finally 0 analystsrate the company as sell with a one year target price of 1,577.33GBX

With a market cap of 0.0 GBX, GlaxoSmithKline PLC has a PE of 2,693 with a one-year low of 1,227.50GBX and a one-year high of 1,716.50GBX.

Brief Synopsis On GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, and respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *